On September 11, PHARMARON fell 3.39% in regular trading, trading at HKD 27.24/share, with turnover of HKD 27.37 million. The decline came amid broad-based weakness across the Life Sciences Tools and Services sector.

On the news front, the life sciences and CXO sector faced collective selling pressure during the session. Among sector peers, WuXi Biologics fell 2.44%, WuXi AppTec dropped 1.78%, Insilico declined 4.55%, and XtalPi slid 4.65%, dragging PHARMARON lower in sympathy. The pullback follows a period of significant institutional accumulation — Morgan Stanley raised its stake to 7.15%, JPMorgan increased its long position to 11.43%, and Citigroup lifted its holding to 5.54% — suggesting short-term profit-taking after a sustained rally. The company reported solid H1 results on August 20, with revenue of RMB 7.595 billion, up 17.92% year-over-year, and new order growth exceeding 30%. Management subsequently raised full-year revenue growth guidance to 15%-20%. Multiple investment banks, including Daiwa (target HKD 38.5), Bank of America (target HKD 38.4), and Morgan Stanley (target HKD 35.6), maintain Buy or Overweight ratings.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)